IL-2K35C-moFA, a Long-Acting Engineered Cytokine with Decreased Interleukin 2 Receptor α Binding, Improved the Cellular Selectivity Profile and Antitumor Efficacy in a Mouse Tumor Model
Open Access
Abstract
Human interleukin 2 (IL-2) has shown impressive results as a therapeutic agent for cancer. However, IL-2-based cancer therapy is limited by strong Treg amplification owing to its high binding affinity to IL-2 receptor α (IL-2Rα) and its short half-life owing to its small molecular size. In this study, we solved these problems using a covalent modification strategy of the IL-2 variant, i.e., substituting cysteine (C) for lysine (K) at position 35, using octadecanedicarboxylic acid through maleimide chemistry, creating IL-2K35C-moFA. IL-2K35C-moFA was equipotent to human IL-2 wild type (IL-2WT) in activating tumor-killing CD8+ memory effector T cells (CD8+ T) and NK cells bearing the intermediate affinity IL-2 receptors, and less potent than IL-2WT on CTLL-2 cells bearing the high-affinity IL-2 receptors. Moreover, it was shown to support the preferential activation of IL-2 receptor β (IL-2Rβ) over IL-2Rα because of the mutation and fatty acid conjugation. In a B16F10 murine tumor model, IL-2K35C-moFA showed efficacy as a single dose and provided durable immunity for 1 week. Our results support the further evaluation of IL-2K35C-moFA as a novel cancer immunotherapy.Keywords
Funding Information
- Key Research and Development Program of Zhejiang Province (CN) (2021C03089)
This publication has 41 references indexed in Scilit:
- A Dicarboxylic Fatty Acid Derivative of Paclitaxel for Albumin-Assisted Drug DeliveryJournal of Pharmaceutical Sciences, 2012
- The role of interleukin-2 during homeostasis and activation of the immune systemNature Reviews Immunology, 2012
- Interleukin-2 Therapy of Metastatic Renal Cell Carcinoma—Predictors of ResponseSeminars in Oncology, 2006
- Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptorProceedings of the National Academy of Sciences, 2006
- Pharmacokinetic Consequences of PegylationDrug Delivery, 2006
- Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in miceCancer Immunology, Immunotherapy, 2004
- PEGylation Confers Greatly Extended Half-Life and Attenuated Immunogenicity to Recombinant Methioninase in PrimatesCancer Research, 2004
- Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemirInternational Journal of Obesity, 2004
- Effect of pegylation on pharmaceuticalsNature Reviews Drug Discovery, 2003
- Heterogeneity of human T-cell growth factor(s) due to variable glycosylationMolecular Immunology, 1981